The incidence of side effects is classified according to the recommendations of the World Health Organization: very often - at least 10%; often - not less than 1%, but less than 10%; infrequently - not less than 0,1%, but less than 1%; rarely - not less than 0.01%, but less than 0.1%; very rarely - less than 0.01%, including single messages.
Monotherapy with pioglitazone
From the nervous system: often - hypoesthesia; infrequently - insomnia.
On the part of the body as a whole: often - weight gain.
Infections and infestations: often - infections of the upper respiratory tract; infrequently sinusitis.
From the side of the organ of vision: often - visual impairment.
Benign and malignant tumors: infrequently - bladder cancer.
Pioglitazone in combination with metformin.
On the part of the hematopoiesis and lymphatic system: often - anemia.
From the side of the organ of vision: often - visual impairment.
From the gastrointestinal tract: infrequently - flatulence.
On the part of the body as a whole: often - weight gain.
From the musculoskeletal system: often - arthralgia, myalgia.
From the nervous system: often a headache.
From the side of the urinary system: often - hematuria.
On the part of the reproductive system: often - erectile dysfunction.
Pioglitazone in combination with sulfonylurea derivatives.
From the organs of hearing and balance: infrequently - dizziness.
From the side of the organ of vision: infrequently - impaired vision.
From the gastrointestinal tract: often - flatulence.
On the part of the body as a whole: often - weight gain; infrequently, weakness.
From the laboratory indicators: increase in lactate dehydrogenase activity in blood plasma.
From the side of metabolism: infrequent - increased appetite, hypoglycemia.
From the nervous system: often - dizziness; infrequently - a headache.
From the side of the urinary system: infrequently - glycosuria, proteinuria.
From the side of the skin: infrequently - a hyperhidrosis.
Pioglitazone in combination with metformin and sulfonylurea derivatives
From the laboratory indicators: increased activity of alanine aminotransferase (ALT), creatinine phosphokinase, decreased hematocrit and hemoglobin.
From the side of metabolism: very often - hypoglycemia.
From the musculoskeletal system: often - arthralgia, myalgia.
Pioglitazone in combination with insulin
From the side of metabolism: often - hypoglycemia.
On the part of the body as a whole: very often - swelling; often - weight gain.
Infections and infestations: often bronchitis.
From the musculoskeletal system: often - back pain, arthralgia.
On the part of the respiratory system: often - shortness of breath.
From the cardiovascular system: often - heart failure.
With long-term use of pioglitazone over 1 year in 6-9% of cases, patients experience edema, mild or moderate, and usually do not require discontinuation of therapy. Visual disturbances appear primarily at the beginning of therapy and are associated with a change in the concentration of glucose in the blood plasma, as well as when taking other hypoglycemic agents.